Preliminary work in our group shows that LDHC is strongly expressed in breast cancer, thereby supporting its potential as a biomarker and/or immunotherapeutic target for breast cancer, including the aggressive triple negative breast cancer subtype. Here, LDHC is linked to breast carcinoma.